Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
NCT03505320 · View on ClinicalTrials.gov ↗
Study Summary
Zolbetuximab is being studied as a treatment for people with cancer in and around the stomach or cancer where the food pipe (esophagus) joins the stomach (gastroesophageal junction cancer). Most people with this type of cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab is thought to work by attaching to Claudin 18.2 in their tumor. This switches on the body's immune system to attack the tumor. There is an unmet medical need to treat people with advanced cancer in and around the stomach or gastroesophageal junction cancer. This study will provide more information on zolbetuximab given by itself and in combination with other treatments in adults with advanced stomach or gastroesophageal junction cancer. The study is currently ongoing globally. People in this study will either be treated with zolbetuximab by itself, with zolbetuximab and chemotherapy, with zolbetuximab and a medicine called pembrolizumab, or zolbetuximab with chemotherapy and a medicine called nivolumab. This study is ongoing, but enrollment in any of the treatment options has been completed. In addition, at this stage of the study, treatment in some of these treatment options has completed. The main aim of this study is to check how well zolbetuximab controls tumors when given by itself. Adults with cancer in and around the stomach or gastroesophageal junction cancer can take part. Their cancer is locally advanced unresectable or metastatic and has the CLDN18.2 marker in a tumor sample. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. They may have been previously treated with standard therapies. People cannot take part if they need to take medicines to suppress their immune system, have blockages or bleeding in their gut, have specific uncontrollable cancers such as symptomatic or untreated cancers in the nervous system, have a specific
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG oxaliplatin
- DRUG fluorouracil
- DRUG leucovorin
- DRUG zolbetuximab
Study Locations (20)
Other
- Site FR33001 — Brest
- Site FR33004 — Paris
- Site IT39005 — Milan
- Site IT39002 — Naples
- Site IT39004 — Padua
- Site IT39003 — Pisa
- Site JP81001 — Chiba
- Site JP81002 — Tokyo
- Site JP81003 — Tokyo
- Site KR82002 — Seongnam-si
- Site KR82001 — Seoul
- Site TW88601 — Taichung
California
- The Angeles Clinic and Research Institute — Los Angeles
- UCLA Medical Center — Santa Monica
New York
- Memorial Sloan Kettering Cancer Center — New York
- Weill Cornell Medical College — New York
Nouvelle-Aquitaine
- Site FR33003 — Pessac
- Site FR33002 — Poitiers
Illinois
- University of Chicago — Chicago
Massachusetts
- Mass General / North Shore Can — Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2018-06-29 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03505320
The ClinicalTrials.gov registry entry for NCT03505320 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 172 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 5 interventions — of which Pembrolizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03505320 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Other, California, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03505320 about?
NCT03505320 is a clinical study titled "A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer". Zolbetuximab is being studied as a treatment for people with cancer in and around the stomach or cancer where the food pipe (esophagus) joins the stomach (gastroesophageal junction cancer). Most people with this type of cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab is though...
What is the current status of trial NCT03505320?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2018-06-29. Estimated completion is 2027-05-31.
What conditions does trial NCT03505320 study?
This clinical trial studies the following conditions: Gastric Cancer, Pharmacokinetics of Zolbetuximab, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin, Pharmacokinetics of Fluorouracil Bolus (5-FU). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03505320?
The interventions under investigation include: Pembrolizumab (DRUG), oxaliplatin (DRUG), fluorouracil (DRUG), leucovorin (DRUG), zolbetuximab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03505320?
This trial is sponsored by Astellas Pharma Global Development, which has 172 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03505320 being conducted?
This trial has 20 study locations across California, Illinois, Massachusetts, New York, Nouvelle-Aquitaine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.